Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05971849 · ClinicalTrials.gov registry record · Phase 1
Dampening the Reproductive Axis With Continuous Kisspeptin
A Phase 1 study, sponsored by Stephanie B. Seminara, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05971849 is a Phase 1 study that has completed, run by Stephanie B. Seminara, MD. The registered enrollment target is 8 participants.
The verdict
NCT05971849, a Phase 1 study, has completed, sponsored by Stephanie B. Seminara, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).
Interventions
- DRUG kisspeptin 112-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-10-06 |
| Est. Completion | 2024-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05971849
The ClinicalTrials.gov registry entry for NCT05971849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephanie B. Seminara, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which kisspeptin 112-121 is the first listed.
NCT05971849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05971849 about?
NCT05971849 is a clinical study titled "Dampening the Reproductive Axis With Continuous Kisspeptin". The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).
What is the current status of trial NCT05971849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-10-06. Estimated completion is 2024-04-27.
What interventions are being tested in trial NCT05971849?
The interventions under investigation include: kisspeptin 112-121 (DRUG).
Who is sponsoring clinical trial NCT05971849?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.